Welcome to the TLDR Biotech newsletter!

TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you!

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a new [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Clinical Trials

Bayer posts hot results in two menopause-associated hot flash trials
Small molecule, menopause - Read more

Closed Loop, Pharmanovia launch a “zesty” drug+software combo therapy
Small molecule, digital health, combination, hypertension - Read more

THE GOOD
Earnings & Finances

Cleveland Clinic non-profit reports; operating margins go up (a bit)
Medical centers, non-profit - Read more

THE GOOD
Fundraises

R3 Vascular $87M raise
Bioresorbable stent, medical device - Read more

THE GOOD
IPOs

Telix Pharmaceuticals potentialy $100M IPO
Radiopharmaceuticals, cancer - Read more

THE GOOD
Lawsuits

Moderna reigns supreme in COVID shot patent case
Covid-19 vaccine, patent law - Read more

THE GOOD
Research

Research links (very rare) COVID vaccine-related blood clots to common cold*
COVID-19, vaccine development - Read more

(*A “Good” story as this research could help us develop safer vaccines in the future)

SPONSORED
Looking to leave the lab and get into sales?

One of the biggest hurdles to overcome in this job market is experience - and the next best thing you can do is get certified in life sciences sales skills.

Succession is running a 4-week “Welcome to Sales Accelerator” to give you the skills you need and help you land your first sales role. Ready to launch your life science sales career? (Spots are filling up for the June cohort.)

Use discount code WELCOMETOSALESTLDR for $100 off!

THE BAD
Approvals & Labels

Jiangsu Hengrui Pharma, Elevar Therapeutic liver cancer combo lands FDA rejection
Antibody, small molecule, combo therapeutic, cancer - Read more

THE BAD
Layoffs

Erasca trims staff and pipeline
Molecular glue, cancer - Read more

THE BAD
Opinions

FTC Deputy Director weighs in on Pharma M&A
Mergers & Acquisitions - Read more [Paywall]

THE UGLY
Approvals & Labels

EMA follows FDA, cracks down on preterm birth drug; safety & efficacy concerns
17-hydroxyprogesterone caproate, preterm birth - Read more

THE UGLY
Opinions

Who doesn’t trust the FDA? This research aimed to find out. - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 100+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.